Once daily ceftriaxone plus amikacin vs three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer

This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. The authors concluded that once daily administration of ceftriaxone plus amikacin was as safe and effective as three times daily administration of ceftazidime plus amikacin in the treatment of febrile neutropenic children and was more cost-effective.